Skip to main content
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. — Investor Relations & Filings

Ticker · BTAI ISIN · US09075P2048 LEI · 549300Y25FYZ0E8LW260 US Manufacturing
Filings indexed 635 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US BTAI

About BioXcel Therapeutics, Inc.

https://www.bioxceltherapeutics.com/

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company that utilizes a proprietary artificial intelligence (AI) platform for drug development. The company focuses on creating transformative medicines in the fields of neuroscience and immuno-oncology. Its AI-driven approach aims to identify new therapeutic uses for existing molecules and novel compounds, potentially accelerating development timelines. The company's lead commercial product is IGALMI™ (dexmedetomidine sublingual film), approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel's late-stage clinical pipeline includes programs investigating treatments for agitation in patients with Alzheimer's disease and other neuropsychiatric conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-15 English
10-Q
Interim / Quarterly Report
2026-05-15 English
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
Regulatory Filings
2026-04-17 English
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
Regulatory Filings
2026-04-01 English
10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
Annual Report FY 2025
2026-03-27 English
8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
Regulatory Filings
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.